How Far Must Medicine Go to Spare One More Operation?

Removing the lesions can help patients breathe and speak more easily. But if they grow back, life has to be arranged around the next operation all over again.

For people with recurrent respiratory papillomatosis, this cycle can last for years. Some hope to preserve as much of their voice as possible. Some worry about becoming short of breath again. Families repeatedly have to plan travel, leave from work, and caregiving. Postponing the next operation—or even going without surgery for a time—is a wish that deserves to be taken seriously.

On October 30, 2026, the US FDA granted accelerated approval to Inovio's VOCERYQ, formerly known as INO-3107, to reduce the number of operations adults need to remove papillomas. It is the first plasmid DNA-based immunotherapy approved in the United States. Behind this new milestone lies a question pursued for half a century and still not fully answered: how can patients be spared some of the burden of repeated treatment?^[1]

1. How repeated surgery takes over family life

The disease is usually associated with persistent infection with HPV type 6 or 11. Lesions often develop in the larynx, around the vocal cords. Most papillomas are benign, but they can cause hoarseness, difficulty speaking, and, in severe cases, impaired breathing. Surgery can remove the lesions, but infection may persist in the tissue, allowing them to grow back. Keeping the airway open, controlling lesions, and protecting the voice as much as possible must all be considered together.^[1][3]

Available data are insufficient to estimate reliably how many people in China have the disease. A study from 12 hospitals published in 2025 does, however, offer long-term information on 361 patients with juvenile-onset disease. Over a median follow-up of 7.2 years, 87% experienced recurrence; under the study's definition of economic burden, 64.3% of the families interviewed incurred catastrophic health expenditure. This hospital-based cohort cannot be directly generalized to all Chinese patients, but it clearly shows the heavy impact on some families.^[2]

Access to surgery also varies in practice. The study noted that many primary-level hospitals lack pediatric ear, nose, and throat specialists, so patients often need referral to higher-level general or children's hospitals. Pediatric airway surgery in particular requires coordination between ENT and anesthesia teams, maintaining ventilation while treating the lesions. Being able to obtain one operation and being able to obtain operations as needed, year after year, place different burdens on a family.^[2][3]

The authors added a caution: fewer recorded operations do not necessarily mean milder disease; they may also reflect delayed care and limited access. This is a possible explanation requiring further study, but it reminds us that when evaluating “fewer surgeries,” we must also ask whether patients' condition and daily lives have actually improved.^[2]

2. A wish pursued for half a century

Today's news can focus our attention on a newly approved drug. A longer view reveals many earlier attempts. Papers on treating laryngeal papillomatosis with “transfer factor” appeared at least as early as 1975. By the 1980s, immune interventions such as interferon had entered clinical studies.^[4]

This history includes hope, but also moments when results failed to withstand longer follow-up or stricter comparisons. The following milestones are supported by original research. They involve different teams and technologies, and do not mean that one particular drug has been in development for fifty years.

1975
Early immune intervention. Research using transfer factor to treat laryngeal papillomatosis shows that investigators were exploring alternatives to surgery early on.^[4]

1988
An early improvement that did not last. A randomized trial of 123 people compared surgery plus interferon with surgery alone. Lesion growth was slower in the combination group during the first six months, but that advantage was not maintained.^[4]

1998–2008
An antiviral drug brings hope—and undergoes testing. Early cases involving local injections of cidofovir drew attention. A 19-person placebo-controlled trial in 2008 found no between-group difference in the number of operations. Uncertainty remained because of the small sample.^[5]

2009–2014
Seeking an approach through the lesions' blood supply. Studies of locally injected bevacizumab and case series of systemic treatment were published, exploring whether inhibiting abnormal blood-vessel formation could control lesions and reduce interventions.^[6]

Beginning in 2020–2021
HPV-targeted immunotherapies enter clinical testing. INO-3107 and PRGN-2012 began enrolling patients in their key early clinical studies, examining whether specific immune responses could translate into disease control.^[7][8]

2025–2026
Immunotherapies gain US approval. Papzimeos was approved in 2025, followed by accelerated approval for VOCERYQ in 2026. The latter still requires a confirmatory study to further establish clinical benefit.^[1][8]

The 1988 interferon trial is especially worth pausing over. There was an early improvement, but continued observation required a more restrained conclusion. The 2008 cidofovir trial also found that lesion scores improved in the drug group, but improved in the placebo group as well. The disease can become less active and then flare again. Observing improvement after treatment therefore still requires judgment against an appropriate comparison.^[4][5]

These studies have built up two kinds of knowledge: new approaches that may help patients, and ways to identify that help more reliably. The latter also requires patient participation, research funding, and time.

3. What does DNA deliver to the immune system?

VOCERYQ seeks to establish an immune response against HPV-infected cells. Here, DNA serves as a set of “manufacturing instructions”: it causes cells to express specific viral antigens, helping the immune system recognize its target and mobilize T cells capable of attacking infected cells. A separate DNA instruction encodes IL-12 to enhance the immune response.^[1][7]

The treatment requires intramuscular injection together with a specialized device that generates brief electrical pulses to help plasmids enter cells, a process called electroporation. Four doses are given over nine weeks. Before treatment begins, visible lesions must still be surgically removed. The aim is to reduce the subsequent need for repeated lesion removal.^[1]

Another immunotherapy, Papzimeos, is already available for the same disease. It uses a non-replicating adenoviral vector to deliver instructions for expressing HPV antigens. Both products aim to strengthen specific immune responses against infected cells; their main differences lie in the delivery platform, antigen design, and method of immune enhancement. Different designs warrant investigation, but clinical outcomes must determine how much additional benefit they provide to patients.^[7][8]

Returning to patients, the central question remains: can this immune response reduce the need for repeated treatment?

4. What does a year without surgery actually establish?

In the VOCERYQ study described in the FDA prescribing information, 32 adults received treatment. The key efficacy analysis included the 26 patients who had undergone at least three operations in the preceding year. During the specified 12-month observation period, 7 needed no further surgery, approximately 27%. “Complete response” here is defined by the absence of surgery; it cannot be directly interpreted as viral clearance or a cure.^[1]

In a separate Papzimeos study, 18 of the 35 patients who received the approved dose needed no surgery during the 12 months after completing the treatment course, approximately 51%. Its prescribing information also reports that 15 remained in that state through 24 months. Some patients who did not achieve a complete response nevertheless benefited from fewer operations.^[8]

These percentages cannot be used to rank the drugs directly. Both studies were small and single-arm, with differences in patient populations, observation windows, and arrangements for removing lesions during dosing. The Papzimeos study allowed additional lesion removal during dosing, and its primary endpoint assessed the year after the last dose. The original INO-3107 study counted surgeries starting after the first dose. The drugs were not compared directly in the same trial.^[8][9]

For a family, time without another operation may be immensely valuable. But scientific assessment must continue. How long does the effect last? Do voice and breathing improve as well? Which patients benefit less? Can repeat dosing maintain the effect, and what risks might it bring? Both drugs can cause adverse reactions such as injection-site reactions. VOCERYQ also involves procedure-related reactions, including the brief muscle contractions caused by electroporation.^[1][8]

Extended follow-up data are available for both approaches. The FDA nevertheless requires a confirmatory study of VOCERYQ involving at least 50 adult and pediatric patients, assessing the need for surgery for at least three years after completion of treatment and comparing results with an appropriate external control or scientifically justified threshold. The approval letter lists 2032 as the submission date for the final study report. This gives a concrete timescale to the question in the title: even after approval, some questions require years of observation.^[1][8][9]

5. China is also looking for ways to reduce surgery

Clinical practice and research in China are also exploring interventions beyond surgery. Bevacizumab is one approach receiving attention. China's 2024 pediatric guideline says it may be considered as adjunctive therapy for patients with rapid progression, frequent operations, or spread into the lower airway. This is a weak recommendation supported by low-quality evidence, and use for this disease is off-label. A dedicated Chinese consensus published in 2026 continues efforts to standardize its use.^[3][11]

Domestically developed therapeutic DNA vaccines are also under development. In its 2026 half-year report, Advaccine disclosed ADV2104 for RRP and recorded that its clinical trial application had been accepted for review in July of that year. This shows that Chinese companies are also exploring specific immune interventions. The filing milestone itself does not establish how many operations the product might spare patients.^[12]

Studies registered in China also include pucotenlimab for RRP and an observational study of benefits following nine-valent HPV vaccination in people who already have the disease. The first explores immune-checkpoint intervention; the second studies the adjunctive role of a prophylactic vaccine. These are different approaches from new therapeutic vaccines, and registration does not mean efficacy has been established.^[13]

The patient populations must be distinguished. The Chinese burden study discussed earlier concerned juvenile-onset patients, whereas both US-approved products have adult indications. Whether children can gain the same benefits requires corresponding evidence. Overseas approval also does not automatically resolve access for Chinese patients. Local approval, cost, equipment, and specialist teams all affect when an advance enters routine care.

6. Turning more choices into more appropriate treatment

As approaches multiply, the questions facing medicine become more specific. We need to identify which patients suit which methods, how to arrange medicines and surgery, when continued observation is appropriate, and when adjustment is needed. Durability, safety, voice and breathing function, and families' costs and time spent obtaining care should all enter the assessment.

In 2026, a position statement on adult RRP management attempted to place HPV-specific immunotherapy, bevacizumab, and surgery within a shared decision pathway. These are expert recommendations, rated as level 5 evidence, and still require testing and refinement. Mature treatment plans gradually emerge through such comparisons, follow-up, and revision, and may differ between patients.^[10]

Looking back over half a century, we can see how one wish has been divided into many researchable questions. Some researchers identify viruses and immune responses, some test new approaches, and others use controls and follow-up to rein in premature judgments. Patients participate, giving designs on paper the chance to be tested in real lives. This work requires sustained funding and professional collaboration, together with honest records of failure and uncertainty.

Public interest in drug development can begin with practical difficulties like these. Seeing both the burden patients bear and how evidence accumulates makes it easier to understand why seemingly modest improvements deserve investment, and to retain patience for scientific questions still unresolved. At the same time, research quality, adequate disclosure, and subsequent verification should remain part of that attention.

One fewer operation may mean one fewer anesthetic, one less recovery period, or one less journey to another city. For patients, the hope is to postpone the next treatment and have more time to organize life on their own terms. Medicine has already traveled a long way in pursuit of that hope, and the journey continues.

Beyond the conclusion, there are questions worth continuing to ask.

Medicine · Science · Ideas and Reading

Follow Before the Conclusion as we stay curious and think independently together.

References and verification notes

Sources current through November 3, 2026. The timeline selects milestones supported by original sources and does not claim any given year as the earliest beginning of treatment research. Studies differ in participants' ages, disease severity, and the way operations were counted. This article does not rank efficacy across trials.

1. FDA, VOCERYQ, October 30, 2026. Approval announcement; prescribing information (administration, efficacy population, and safety); accelerated approval letter (confirmatory-study requirements and the 2032 final-report milestone).
2. Dun et al., International Journal of Infectious Diseases, 2025. Full text of the Chinese multicenter study of juvenile-onset RRP, 2011–2021; PubMed abstract. The 361 participants came from 12 hospitals; the cost study combined medical records and interviews. The authors defined catastrophic health expenditure as out-of-pocket medical spending exceeding 40% of annual household disposable income per capita. The 64.3% is the proportion in this cohort under that definition, not a national patient percentage or health-insurance statistic for that year. The influence of access on surgical records is a possible explanation discussed by the authors.
3. Chinese guideline for diagnosis and treatment of juvenile-onset RRP (2024), English version published in 2025. Full guideline. Covers referral, airway and anesthesia management, instrument selection, and the 2D recommendation and off-label-use information for bevacizumab.
4. Early immune interventions. Quick et al., 1975, transfer factor treatment of laryngeal papillomatosis; Healy et al., NEJM, 1988, 123-person randomized interferon trial. The 1975 paper marks a historical research milestone; it is not used here to assess the method's clinical efficacy.
5. Cidofovir research. Snoeck et al., 1998, early study of 17 patients; McMurray et al., 2008, 19-person randomized, double-blind, placebo-controlled study. The latter observed no between-group difference in the number of operations. A small study cannot establish that treatment is ineffective for all patients.
6. The anti-angiogenic approach. Zeitels et al., 2009, pilot study of local bevacizumab with KTP laser; Mohr et al., 2014, case series of systemic bevacizumab. These were early investigations, not equivalent to large-scale controlled evidence.
7. Morrow et al., Nature Communications, 2025. Phase 1/2 INO-3107 study; PubMed abstract. Covers enrollment in 2020–2021, plasmid design, and immunological results. The paper's whole-group analysis differs from the 26-person analysis population in the FDA prescribing information; the key approval figures here follow the FDA information.
8. Clinical and regulatory information for Papzimeos. Norberg et al., Lancet Respiratory Medicine, 2025, key phase 1/2 study; FDA, August 14, 2025, approval announcement; prescribing information (51% complete response at one year and 43% sustained complete response at two years).
9. Amin et al., The Laryngoscope, 2025. Extended follow-up study of INO-3107. This retrospective extension included 28 of the original 32 participants, with interpretive limitations from loss to follow-up/non-consent to further participation and subsequent use of other treatments. It also states that the original study counted subsequent surgeries from Day 0.
10. RRP Foundation position statement on adult RRP management, The Laryngoscope, 2026. Original article. Proposes a management pathway; the authors rate the evidence as level 5. It is presented here as expert advice.
11. Expert consensus on bevacizumab for RRP (2026 edition), Chinese Journal of Oncology Prevention and Treatment. National science and technology journal platform record and abstract. Used to confirm publication of a dedicated Chinese consensus, not to generalize efficacy and safety across different populations.
12. Advaccine's primary company disclosures, 2026. July 8 announcement of acceptance of the ADV2104 clinical trial application; August 27 half-year report. This article lists only verified filing milestones. It does not infer the highest clinical phase or recruitment status as of writing from these historical records, nor treat orphan-drug or rare-pediatric-disease designation as marketing approval.
13. Chinese Clinical Trial Registry. Pucotenlimab study, ChiCTR2600124445, registered May 2026; Beijing Tongren Hospital HPV vaccine observational study, ChiCTR2500103158, registered May 2025. This article confirms only registered content and does not infer actual enrollment progress or clinical efficacy from registration.